Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919555 | 0.99 | CA14 (0.58) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL7264039 | 0.96 | CA14 (0.58) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL7270004 | 0.96 | CA14 (0.58) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL3472122 | 0.96 | CA14 (0.62) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL1919913 | 0.94 | CA14 (0.60) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL4370840 | 0.94 | CA14 (0.59) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL18258336 | 0.93 | CA14 (0.53) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL7631999 | 0.93 | CA14 (0.62) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL13055412 | 0.93 | CA14 (0.64) | CA14TDP1MAOAMAOBCA1 | |
| SCHEMBL10181287 | 0.92 | CA14 (0.53) | CA14TDP1MAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260184-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | UNIV KANSAS (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260184-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | UNIV KANSAS (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260184-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | TLR7, TLR8, TLR3 | CA14 4708/4885TDP1 1837/4885MAOA 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.